TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02652624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC administered orally once daily with food
Study: NCT01770509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMBM
Description: Daily application of NMBM in addition to compression therapy
Study: NCT02652624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: ATV 300 mg capsules administered orally once daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: RTV 100 mg tablets administered orally once daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally once daily with food
Study: NCT01770509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression garments
Description: Compression garments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression garments
Description: Compression garments
Study: NCT01972373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR fluorescence endoscopy
Description: 48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
Study: NCT02374476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar Ablation
Description: Patients will undergo bipolar ablation if unipolar ablation unsuccessful
Study: NCT02652624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food
Study: NCT00654628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
Study: NCT02310659

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02616224

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was administered in this study.
Study: NCT01639170

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiograph
Description: All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the
Study: NCT06703086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine Hydrochloride group
Description: The patient will be given a nutritional plan, moderate aerobic exercise with a goal of 10,000 steps or 150 min per week; and the phytopharmaceutical Berberine will be taken 3 tablets ( 500 mg) every 8 hours for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional plan
Description: nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional plan
Description: nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional plan
Description: nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: controlled moderate aerobic exercise
Description: controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: controlled moderate aerobic exercise
Description: controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week.
Study: NCT02374476

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Ablation
Description: Patients will undergo bipolar ablation if unipolar ablation unsuccessful
Study: NCT00751088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MiniArc positioning
Description: Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure.
Study: NCT03721198

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Acidulated phosphorous flouride
Description: Acidulated phosphorous flouride is used to prevent white spot lesions
Study: NCT03681561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
Study: NCT03721198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer varnish
Description: Resin modified glass ionomer varnish is used to prevent white spot lesions
Study: NCT04410926

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corrective exercises
Description: The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corrective exercises
Description: The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles for 30 minutes. The surface electrodes were placed over the abductor halluces. The control group received placebo NMES with no current stimulation.
Study: NCT03863366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 1mg prucalopride tablet, encapsulated in white capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose placebo tablet, encapsulated in white capsule
Study: NCT01362907

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lens
Description: Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lens
Description: Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lens
Description: Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lens
Description: Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
Study: NCT02502357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing Statements
Description: Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, \[the participant\] will feel very comfortable and \[the participant\] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, \[the participant\] will be hungry. \[The participant\] will be thirsty and urinate easily.
Study: NCT01469325

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
Study: NCT03780179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMRvaxpro
Description: MMRvaxpro vaccine
Study: NCT03731325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking Group
Description: Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking Group
Description: Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision.
Study: NCT03780179

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00501540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
Study: NCT03515460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar oral load
Description: The individuals will receive a sugar oral load (high sugar meal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fat oral load
Description: The individuals will a receive fat oral load (high fat meal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar and fat oral load
Description: The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
Study: NCT04354259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1A
Description: Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
Study: NCT06468007

Intervention type: DRUG
Intervention: Methylprednisolone Tablet
Description: Patients receiving equipotent doses of methylprednisolone or prednisolone . Dosages will be determined at the discretion of the treating physician, customized for the specific clinical need in accordance with local guidelines.
Study: NCT04354259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1A
Description: Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
Study: NCT00073905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine plus gemcitabine
Description: capecitabine plus gemcitabine
Study: NCT04140994

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS device
Description: Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS device
Description: Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
Study: NCT01285739

Intervention type: OTHER
Intervention: WBC, biomarkers, TBA, chest X ray
Description: The above cited parameters were recorded and investigated every six months; chest X ray when needed.

Intervention type: OTHER
Intervention: WBC, biomarkers, TBA, chest X ray
Description: The above cited parameters were recorded and investigated every six months; chest X ray when needed.
Study: NCT03686124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203 product- flat dose
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203CD8 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203CD8 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
Study: NCT02628275

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate to vigorous physical activity
Description: 55-90% maximum heart rate for 150min/week (current recommendations)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light physical activity
Description: 40-55% maximum heart rate for 150min/week
Study: NCT02099721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD or CRT-D Device
Description: Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD or CRT-D Device
Description: Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
Study: NCT03686124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203CD8 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203CD8 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203CD8 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA203CD8 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab (Opdivo®)
Description: Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics
Study: NCT02099721

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD or CRT-D Device
Description: Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
Study: NCT03686124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics
Study: NCT00830193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
Study: NCT03686124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics
Study: NCT00830193

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D5W Placebo
Description: Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).